Regeneron’s gene therapy for otoferlin-related hearing loss – a genetic cause of deafness – has restored hearing to normal levels in one profoundly deaf child within just 24 weeks.
The result comes from a phase 1/2 study of the company’s experimental adeno-associated virus (AAV) gene therapy DB-OTO and was seen in a child who was born deaf and treated at 11 months of age.
